Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of **propofol**, **remifentanil**, and **atracurium** used for induction and maintenance of general anesthesia, especially in surgeries or procedures where rapid onset, profound analgesia, muscle relaxation, and rapid recovery are desired. **Propofol** is an intravenous hypnotic agent facilitating loss of consciousness; **remifentanil** is a potent, ultra-short acting opioid analgesic providing pain relief and blunting responses to surgical stimuli; **atracurium** is a non-depolarizing neuromuscular blocker producing skeletal muscle relaxation, aiding procedures such as intubation and mechanical ventilation. The combination allows lower doses of each component, potentially reducing side effects while providing synergistic anesthetic and analgesic effects. This regimen is commonly used in operating rooms and intensive care settings for its safety, efficacy, and rapid recovery profile[1][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propofol + remifentanil + atracurium.